Within 6 months after ID, the variation (%) in HbA1c values was more marked among incident treatments of fixed-dose combination of metformin + SGLT2i (−15.7%), SGLT2i (−12.8%) and insulin (−12.7%), as compared to other AD classes (p-values < 0.001) (Figure 4). This evidence concerns the gene INS and Alzheimer disease.